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Background: Enzymes of the cytochrome P450 3A
(CYP3A) family are responsible for the metabolism of
>50% of currently prescribed drugs. CYP3A5 is ex-
pressed in a limited number of individuals. The absence
of CYP3A5 expression in 70% of Caucasians was
recently correlated to a genetic polymorphism
(CYP3A5*3). Because CYP3A5 may represent up to 50%
of total CYP3A protein in individuals polymorphically
expressing CYP3A5, it may have a major role in variation
of CYP3A-mediated drug metabolism. Using sequenc-
ing, have been identified (Hustert et al. Pharmacogenet-
ics 2001;11:773–9; Kuehl et al. Nat Genet 2001;27:383–91)
variant alleles *2 through *7 for CYP3A5. Detection of
CYP3A5 variant alleles, and knowledge about their
allelic frequency in specific ethnic groups, is important
to establish the clinical relevance of screening for these
polymorphisms to optimize pharmacotherapy.
Methods: In a group of 500 healthy Dutch Caucasian
blood donors, we determined the allelic frequency of
the CYP3A5*2, *3, *4, *5, *6, and *7 alleles by use of
newly developed PCR-restriction fragment length poly-
morphism assays.
Results: The frequency of the defective CYP3A5*3 allele
in the Dutch Caucasian population was 91%, followed
by the CYP3A5*2 (1%) and CYP3A5*6 (0.1%) alleles. The
CYP3A5*4, *5, and *7 alleles were not detected.
Conclusions: On the basis of its allelic frequency,
screening for the CYP3A5*3 allele in the Caucasian
population is extremely relevant. In addition, screening
for the CYP3A5*2 allele may be taken into consideration
in individuals heterozygous for the CYP3A5*3 allele.
The CYP3A5*4, *5, *6, and *7 alleles have low allelic
frequencies that do not support initial screening.
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The CYP3A isoenzymes constitute the largest portion of
cytochrome P450 protein in the liver and small intestine
(1–3). The four members of this subfamily, CYP3A4,
CYP3A5, CYP3A7, and CYP3A43 (4, 5), are located adja-
cent to each other on chromosome 7q21 and are respon-
sible for the metabolism of 50–60% of all currently
prescribed drugs. In addition, two pseudogenes,
CYP3AP1 and CYP3AP2, have been identified (6 ). To
date, CYP3A4 has been regarded as the most important
enzyme of this subfamily because it forms the bulk of
CYP3A protein and mRNA in the liver in most individu-
als (1–3). Its catalytic activity may show up to 90-fold
variation (7 ). CYP3A7 is expressed mainly during fetal life
where it accounts for 50% of the total CYP protein (8 ).
After birth, expression is usually silenced. For the recently
described CYP3A43, no protein expression data are cur-
rently available (9 ). CYP3A5 protein was previously de-
tected in the livers of some, but not all, adult Caucasian
individuals (8, 10–14). The basis for this variation in
expression was not known.
In a recent study, Kuehl et al. (15 ) demonstrated that
only people with at least one CYP3A5*1 allele actually
expressed CYP3A5 protein. Using DNA sequencing, they
identified the CYP3A5*3 and *6 alleles. The single-nucle-
otide polymorphisms in these alleles produced alternative
splicing and protein truncation and thus absence of
CYP3A5 activity. In another study, the livers of 10% of
Caucasian individuals expressed CYP3A5 to a high extent
(high expressers), whereas the remaining individuals
showed on average nine times less activity (low express-
ers) (7 ). The major determinant for this variation in
expression was a single-nucleotide polymorphism at po-
sition 6986, which in the g.6986G allele (CYP3A5*3) led to
alternative splicing of CYP3A5 transcripts and absence of
CYP3A5 protein; the g.6986A allele (CYP3A5*1) correlated
with high expression (7, 15). Because CYP3A5 may rep-
resent up to 50% of the total hepatic CYP3A content in
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people expressing CYP3A5, this gene may be the most
important genetic contributor to interindividual and in-
terracial differences in CYP3A-dependent drug clearance.
Detection of CYP3A5 variant alleles, and knowledge
about the allelic frequencies in the population, will be
extremely useful in establishing the clinical relevance of
CYP3A5 genotyping to optimize pharmacotherapy. To
date, several variant alleles have been identified
(CYP3A5*2 through *7) by sequencing (7, 10, 15, 16). For
screening purposes, we developed PCR-restriction frag-
ment length polymorphism (PCR-RFLP) assays for the
detection of CYP3A5 variant alleles. We report here the
allelic frequencies of CYP3A5 variant alleles in a group of
500 healthy Dutch Caucasian volunteers.
Materials and Methods
samples and dna isolation
After receiving informed consent, we obtained EDTA-
whole blood from 500 healthy Dutch Caucasian volun-
teers. We isolated genomic DNA from 300 L of blood
with the GenomicPrep Blood DNA Isolation Kit (Amer-
sham Pharmacia Biotech) and estimated DNA yields by
measuring the absorbance at 260 nm (A260). The Medical
Ethical Committee of the University Hospital Rotterdam
approved the study.
pcr-rflp for cyp3a5 variant alleles
For a 50-L PCR, we used 50 ng of genomic DNA. The
PCR mixture contained 1 buffer [10 mM Tris-HCl, pH
8.3, 1.5 mM MgCl2, 50 mM KCl, and 10 mg/L gelatin
(Perkin-Elmer)], 0.2 mM each of the deoxynucleotide
triphosphates (Roche), 1.25 U of AmpliTaq Gold (Perkin-
Elmer), and 40 pmol each of the forward and reverse
primers (Table 1). The underlined nucleotides are mis-
matches with the CYP3A5 sequence, creating restriction
sites in the PCR product. PCR conditions were as follows:
7 min at 94 °C; 35 cycles of 1 min at 94 °C, 1 min at 55 °C,
and 1 min at 72 °C; and finally 7 min at 72 °C. The PCR
product was sequenced, confirming that indeed only the
CYP3A5 gene was amplified. The PCR product (10 L)
was then digested with the appropriate restriction en-
zyme (Roche; Table 1) in a total volume of 15 L for 2 h at
37 °C and subsequently analyzed on a 4% agarose/Tris-
borate-EDTA gel with ethidium bromide staining. The
fragments obtained for wild-type and variant alleles are
indicated in Table 1. We confirmed the presence of variant
alleles of CYP3A5 by direct sequencing of the PCR prod-
uct on an automated ABI 310 capillary sequencer (Perkin-
Elmer), using the Big Dye Terminator Cycle Sequencing
Kit (Perkin-Elmer).
Results
On the basis of the published CYP3A5 variant alleles, we
developed specific PCR-RFLP tests for CYP3A5*2 through
*7 and applied those in a large-scale genotyping study on
samples obtained from 500 healthy Caucasian volunteers
(Fig. 1). The frequency of individuals that were wild type,
heterozygous, or homozygous for the variant alleles is
depicted in Table 2. The CYP3A5*3 allele was abundantly
present in our population, with an allelic frequency of
91.7%. Only one individual was homozygous wild type
for CYP3A5*3. The CYP3A4*2 allele was found in 10
individuals, all heterozygotes, giving an allelic frequency
of 1%. One individual was heterozygous for the
CYP3A5*6 allele. The CYP3A5*4, *5, and *7 alleles were
not detected in our study population. Among the 84
persons who were heterozygous or wild type for the
CYP3A5*3 allele, only one was also heterozygous for
another variant allele (CYP3A5*2). Because heterozygotes
and wild types for CYP3A5*3 may have CYP3A5 activity,
we estimate that 83% of Dutch Caucasians do not have
CYP3A5 enzymatic activity.
Discussion
CYP3A enzymes are the predominant cytochrome P450
proteins in the human liver and play an important role in
Table 1. PCR-RFLP primers, size of PCR product, restriction enzymes used, and sizes of fragments obtained with wild-type
and variant alleles for CYP3A5.
CYP3A5
allele Primersa
PCR product
size, bp Enzyme
Fragment sizes, bp
Wild-type allele Variant allele
*2 5-CTGTTTCTTTCCTTCCAGGC-3 269 Tasl 269 182, 87
5-CTCCATTTCCCTGGAGACTTG-3
*3 5-CATCAGTTAGTAGACAGATGA-3 293 Sspl 148, 125, 20 168, 125
5-GGTCCAAACAGGGAAGAAATA-3
*4 5-TCGACTCTCTCAACAATCCTC-3 281 Taql 261, 20 241, 20
5-AAAGTGTGTGAGGGCTCTCGA-3
*5 5-CCATGAAGATCACCACAACT-3 240 NlaIII 226, 14 189, 37, 14
5-CCTGTCCCCAGATTCATGC-3
*6 5-GTGGGGTGTTGACAGCTAAAG-3 495 Ddel 230, 137, 103, 25 230, 137, 128
5-TGGAAGATGATTCAGCAGATAGT-3
*7 5-CTTCAATAGTACTGCATGGAC-3 108 Ddel 61, 24, 22 41, 24, 22, 20
5-CTGTACCACGGCATCATAGCT-3
a Mismatches with the CYP3A5 sequence are underlined.
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the metabolism of numerous exogenous and endogenous
substrates. CYP3A5 is polymorphically expressed and
may account for up to 50% of CYP3A content (15 ).
Recently, six variant alleles were described (7, 15). Ho-
mozygosity for the allele g.6986G was strongly correlated
with decreased CYP3A5 activity [factor of 2–3 (15 )],
whereas the wild-type CYP3A5*1 allele (g.6986A), present
in either homozygous or heterozygous form, correlated
with high CYP3A5 activity. In addition, individuals with
a CYP3A5*1 allele had threefold higher total CYP3A
protein when compared with individuals homozygous for
CYP3A5*3 (15). Thus, CYP3A5 expression may be the
most important factor determining the total CYP3A con-
tent of the human liver.
In a large-scale screening for CYP3A5 variant alleles
among 500 healthy individuals, we conclude that the
CYP3A5*3 allele is abundantly present in the Dutch
Caucasian population, displaying an allelic frequency of
91%. This finding is in agreement with the reported
frequency of 95% found in 183 samples from Caucasian
patients from Germany and Switzerland (7 ). For compar-
ison, the CYP3A5*3 allele was detected in 73% of Chinese,
71% of Japanese, 70% of Korean, and 27% of African-
American individuals (7 ). The CYP3A5*2 allele, encoding
a g.27289C3A allele in exon 11, was found in 2% of the
individuals (allelic frequency, 1%) and may thus be re-
garded as a genetic polymorphism in this population (17 ).
A previous study involving 19 Caucasian individuals
reported an allelic frequency of 5% (n  19) (10 ). This
allele was not found when 45 African-American genomic
DNA samples were investigated, suggesting that in this
ethnic group the allelic frequency is 1% (7 ). Heterozy-
gosity for the CYP3A5*2 allele, however, may potentially
affect CYP3A5 expression in individuals who are already
heterozygous for CYP3A5*3. We found only one individ-
ual heterozygous for both the CYP3A5*2 and *3 alleles,
and this individual may thus lack CYP3A5 activity de-
spite being heterozygous for the CYP3A5*3 allele. The
allelic frequencies of the CYP3A5*4, *5, *6, and *7 alleles
were 0.1%, and these variant alleles are therefore re-
garded as less relevant for screening purposes in the
Caucasian population. In African Americans, the
CYP3A5*6 allele (a g.14690G3A variant in exon 2, leading
to the skipping of exon 7) has an allelic frequency of 13%
(n  45) (7 ), suggesting a significant difference in the
distribution of this allele between African Americans and
Caucasians. This also holds for the CYP3A5*7 allele,
which encodes a single nucleotide (T) insertion at g.27131
that leads to termination of the open reading frame; this
allele was found in 9 of 45 African Americans, giving an
allelic frequency of 10% (7 ). Apparently, the CYP3A5*6
and/or the CYP3A5*7 alleles do not cosegregate with the
CYP3A5*3 allele in Caucasians, as was suggested for
African Americans (7 ). On the basis of the CYP3A5
variant alleles detected in our group of 500 Dutch Cauca-
sians, we deduce that 83% may have low expression of
CYP3A5. This is in agreement with the finding that 10% of
Caucasians were high expressers of CYP3A5 (7).
In conclusion, we showed that screening for the
CYP3A5*3 alleles is relevant in the Caucasian population.
Genotyping for the CYP3A5*2 allele in CYP3A5*3 het-
erozygotes may subsequently be performed. In addition,
we presented simple DNA-based tests that can be used to
investigate interindividual differences in CYP3A5 expres-
sion. This will greatly facilitate studies on the relevance of
pharmacogenetics for CYP3A genes with respect to dis-
ease risk and to the pharmacokinetics and pharmacody-
namics of many drugs.
Fig. 1. PCR-RFLP analyses for CYP3A5 variant alleles.
(A), CYP3A5*2; (B), CYP3A5*3; (C), CYP3A5*6. M, 50-bp DNA ladder; wt, wild type; het, heterozygote; N, negative control (water); P, undigested PCR product; hom,
homozygous variant.
Table 2. Allelic frequencies of CYP3A5 variant alleles in
the Dutch Caucasian population (n  500).
CYP3A5
allele AAa change
Wild
type Heterozygotes Homozygotes
Allelic
frequency
*2 T398N 0.980 0.020 0.000 0.010
*3 Splicing
Defect
0.002 0.167 0.831 0.917
*4 Q200R 1.000 0.000 0.000 0.000
*5 Splicing
Defect
1.000 0.000 0.000 0.000
*6 Splicing
Defect
0.998 0.002 0.000 0.001
*7 Frameshift 1.000 0.000 0.000 0.000
a AA, amino acid.
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